A detailed history of Clark Financial Services Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Clark Financial Services Group Inc holds 6,085 shares of BMY stock, worth $337,413. This represents 0.27% of its overall portfolio holdings.

Number of Shares
6,085
Previous 6,097 0.2%
Holding current value
$337,413
Previous $330,000 23.33%
% of portfolio
0.27%
Previous 0.4%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $483 - $635
-12 Reduced 0.2%
6,085 $253,000
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $8,060 - $9,139
-168 Reduced 2.68%
6,097 $330,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $1,599 - $1,909
-33 Reduced 0.52%
6,265 $321,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $5,731 - $6,408
-99 Reduced 1.55%
6,298 $365,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $318 - $353
-5 Reduced 0.08%
6,397 $409,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $5,125 - $5,813
78 Added 1.23%
6,402 $444,000
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $4,930 - $5,838
72 Added 1.15%
6,324 $454,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $4 - $2,535
33 Added 0.53%
6,252 $444,000
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $6,516 - $7,814
106 Added 1.73%
6,219 $455,000
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $7,293 - $8,502
-136 Reduced 2.18%
6,113 $381,000
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $83,311 - $97,588
1,408 Added 29.08%
6,249 $369,000
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $11,639 - $12,674
188 Added 4.04%
4,841 $323,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $93,994 - $105,716
-1,584 Reduced 25.4%
4,653 $294,000
Q2 2020

Aug 12, 2022

BUY
$54.82 - $64.09 $341,912 - $399,729
6,237 New
6,237 $481,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $118B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Clark Financial Services Group Inc Portfolio

Follow Clark Financial Services Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clark Financial Services Group Inc , based on Form 13F filings with the SEC.

News

Stay updated on Clark Financial Services Group Inc with notifications on news.